0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

On Lymphokines, Cytokines, and Breakthroughs

Charles G. Moertel, MD
JAMA. 1986;256(22):3141. doi:10.1001/jama.1986.03380220107034.
Text Size: A A A
Published online

Advanced cancer will take the lives of almost half a million Americans this year. Certainly, any claim of therapeutic accomplishment in this area will attract major public interest. In recent times, this interest has been focused on the lymphokines and cytokines, natural substances that man produces as a defense against the diseases that may afflict him. Through ingenious recombinant DNA technologies, these substances can be produced in quantities sufficiently large to permit therapeutic application. Numbered among these are the interferons, tumor necrosis factor, and the interleukins.

In this issue of The Journal, a group of investigators present a second report1 of their work with high doses of interleukin 2 (IL-2) used either alone or, as first reported,2 in combination with lymphokine-activated killer (LAK) cells. Following their first publication, these authors described their work as a "breakthrough"; since this claim bore the imprimatur of the National Cancer Institute, it

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();